Cannabinoids, Neural Synchrony, and Information Processing
- Registration Number
- NCT00708994
- Lead Sponsor
- Yale University
- Brief Summary
The study examines the effects of delta-9-tetrahydrocannabinol (Δ9-THC), the principal active ingredient of cannabis, on neural synchrony. Neural synchrony is studied using electroencephalography (EEG).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
- Men and women aged 18 and 55 years (extremes included) on the day of the first dosing.
- Exposed to cannabis at least once.
Exclusion Criteria
- Cannabis naïve
- Positive pregnancy screen during screening
- Hearing deficits
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Placebo Placebo • Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes THC THC * Very low dose (0.0015 mg/kg = 0.21 mg in a 70kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes. * Low dose (0.015 mg/kg = 1.05 mg in a 70kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or "joint". Administered intravenously over 10 minutes. * Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/2 of a marijuana cigarette, or "joint". Administered intravenously over 10 minutes.
- Primary Outcome Measures
Name Time Method EEG +30 Clinician Administered Dissociative Symptoms Scale, Positive and Negative Symptom Scale, Visual Analog Scale Baseline, +10, +80
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
VA Connecticut Healthcare System
🇺🇸West Haven, Connecticut, United States